FY2028 Earnings Estimate for PROCEPT BioRobotics Co. Issued By Leerink Partnrs (NASDAQ:PRCT)

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Equities researchers at Leerink Partnrs dropped their FY2028 EPS estimates for shares of PROCEPT BioRobotics in a research note issued on Friday, August 2nd. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of $0.09 for the year, down from their prior estimate of $0.10. The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.93) per share.

Several other equities research analysts also recently issued reports on PRCT. Piper Sandler raised their price objective on shares of PROCEPT BioRobotics from $67.00 to $75.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. TD Cowen boosted their price objective on shares of PROCEPT BioRobotics from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, May 6th. Truist Financial restated a “buy” rating and issued a $74.00 target price (down from $79.00) on shares of PROCEPT BioRobotics in a research note on Friday, August 2nd. Finally, Wells Fargo & Company raised their price target on shares of PROCEPT BioRobotics from $67.00 to $69.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $66.00.

PROCEPT BioRobotics Stock Performance

PRCT opened at $60.58 on Monday. The company has a quick ratio of 7.44, a current ratio of 8.52 and a debt-to-equity ratio of 0.19. The stock’s 50 day moving average price is $64.22 and its two-hundred day moving average price is $56.67. The firm has a market capitalization of $3.12 billion, a P/E ratio of -28.58 and a beta of 1.00. PROCEPT BioRobotics has a 12-month low of $24.83 and a 12-month high of $77.00.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.02. The company had revenue of $53.35 million during the quarter, compared to analysts’ expectations of $50.10 million. PROCEPT BioRobotics had a negative net margin of 58.73% and a negative return on equity of 36.86%. The business’s quarterly revenue was up 61.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.56) earnings per share.

Insider Transactions at PROCEPT BioRobotics

In related news, EVP Hisham Shiblaq sold 26,046 shares of PROCEPT BioRobotics stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $68.24, for a total value of $1,777,379.04. Following the completion of the transaction, the executive vice president now directly owns 55,860 shares of the company’s stock, valued at $3,811,886.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other PROCEPT BioRobotics news, EVP Alaleh Nouri sold 10,000 shares of the stock in a transaction on Monday, June 17th. The stock was sold at an average price of $62.18, for a total value of $621,800.00. Following the transaction, the executive vice president now directly owns 52,472 shares in the company, valued at approximately $3,262,708.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Hisham Shiblaq sold 26,046 shares of PROCEPT BioRobotics stock in a transaction on Monday, June 10th. The shares were sold at an average price of $68.24, for a total value of $1,777,379.04. Following the completion of the sale, the executive vice president now directly owns 55,860 shares of the company’s stock, valued at $3,811,886.40. The disclosure for this sale can be found here. Company insiders own 17.40% of the company’s stock.

Hedge Funds Weigh In On PROCEPT BioRobotics

Large investors have recently made changes to their positions in the company. Amalgamated Bank raised its holdings in PROCEPT BioRobotics by 5.8% during the 4th quarter. Amalgamated Bank now owns 5,804 shares of the company’s stock worth $243,000 after purchasing an additional 316 shares during the last quarter. Essex Investment Management Co. LLC raised its stake in shares of PROCEPT BioRobotics by 0.6% during the first quarter. Essex Investment Management Co. LLC now owns 60,116 shares of the company’s stock worth $2,971,000 after buying an additional 336 shares during the last quarter. Arizona State Retirement System lifted its holdings in PROCEPT BioRobotics by 2.8% in the second quarter. Arizona State Retirement System now owns 12,840 shares of the company’s stock valued at $784,000 after buying an additional 350 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in PROCEPT BioRobotics by 4.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,913 shares of the company’s stock valued at $606,000 after buying an additional 408 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in PROCEPT BioRobotics by 5.7% in the fourth quarter. Principal Financial Group Inc. now owns 10,588 shares of the company’s stock valued at $444,000 after acquiring an additional 568 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).